Vertex Debt to Equity

VRTX
 Stock
  

USD 316.40  0.07  0.0221%   

Vertex Pharmaceutic fundamentals help investors to digest information that contributes to Vertex Pharmaceutic's financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceutic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceutic stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Long Term Debt to Equity is likely to rise to 0.05 in 2022. Debt to Equity Ratio is likely to rise to 0.05 in 2022.

Vertex Debt to Equity Analysis

Vertex Pharmaceutic's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
 2019 2020 2021 2022 (projected)
Receivables633.52 M885.35 M1.14 B1.23 B
Inventories167.5 M280.78 M353.1 M380.98 M
D/E 
 = 
Total Debt 
Total Equity 
More About Debt to Equity | All Equity Analysis

Current Vertex Pharmaceutic Debt to Equity

    
  0.06 %  
Most of Vertex Pharmaceutic's fundamental indicators, such as Debt to Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vertex Pharmaceutic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Vertex Debt to Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Vertex Pharmaceutic is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Debt to Equity. Since Vertex Pharmaceutic's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vertex Pharmaceutic's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vertex Pharmaceutic's interrelated accounts and indicators.

Vertex Debt to Equity Historical Pattern

Today, most investors in Vertex Pharmaceutic Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vertex Pharmaceutic's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's debt to equity growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Vertex Pharmaceutic debt to equity as a starting point in their analysis.
   Vertex Pharmaceutic Debt to Equity   
Share
       Timeline  
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Compare to competition

Vertex Shareholders Equity

Shareholders Equity

10.9 Billion

Vertex Pharmaceutic Shareholders Equity is fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Shareholders Equity of 10.1 Billion in 2021
According to the company disclosure, Vertex Pharmaceutic has a Debt to Equity of 0.063%. This is 99.88% lower than that of the Healthcare sector and 99.67% lower than that of the Biotechnology industry. The debt to equity for all United States stocks is 99.87% higher than that of the company.

Vertex Debt to Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceutic's direct or indirect competition against its Debt to Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceutic could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceutic by comparing valuation metrics of similar companies.
Vertex Pharmaceutic is currently under evaluation in debt to equity category among related companies.

Vertex Pharmaceutic Current Valuation Drivers

We derive many important indicators used in calculating different scores of Vertex Pharmaceutic from analyzing Vertex Pharmaceutic's financial statements. These drivers represent accounts that assess Vertex Pharmaceutic's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vertex Pharmaceutic's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee114.56 K838.76 K392.27 K795.36 K600.54 K647.95 K
Revenue Per Employee1.08 M1.22 M1.39 M1.82 M1.94 M2.1 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA103.26 M706.76 M1.5 B3.26 B2.91 B3.14 B

Vertex Pharmaceutic ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vertex Pharmaceutic's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vertex Pharmaceutic's managers, analysts, and investors.
Environment Score
Governance Score
Social Score

Vertex Fundamentals

About Vertex Pharmaceutic Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceutic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceutic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceutic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Long Term Debt to Equity 0.05  0.05 
Debt to Equity Ratio 0.05  0.05 
Average Equity1.1 B1.2 B

Be your own money manager

Our tools can tell you how much better you can do entering a position in Vertex Pharmaceutic without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Analysis Now

   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
All  Next Launch Module

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Also, please take a look at Vertex Pharmaceutic Piotroski F Score and Vertex Pharmaceutic Altman Z Score analysis. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for analysis

When running Vertex Pharmaceutic price analysis, check to measure Vertex Pharmaceutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceutic is operating at the current time. Most of Vertex Pharmaceutic's value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceutic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vertex Pharmaceutic's price. Additionally, you may evaluate how the addition of Vertex Pharmaceutic to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Is Vertex Pharmaceutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceutic. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.095
Market Capitalization
80.9 B
Quarterly Revenue Growth YOY
0.18
Return On Assets
0.14
Return On Equity
0.29
The market value of Vertex Pharmaceutic is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceutic's value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceutic's market value can be influenced by many factors that don't directly affect Vertex Pharmaceutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceutic's value and its price as these two are different measures arrived at by different means. Investors typically determine Vertex Pharmaceutic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.